Starting on August 10, 2017, patients with a valid Ontario health card will be able to access Mifepristone/Misoprostol (Mifegymiso) at no cost.
Pharmacies will be reimbursed through the public drug program for $337.25, which includes both the mark-up and dispensing fee. More details about claims submissions can be found in the FAQ. The approximate list price of Mifegymiso is $300. Pharmacies are advised to check with their respective wholesalers to obtain more specific information on cost and availability or contact the manufacturer to order directly.
It is important to note that in order to dispense Mifegymiso, pharmacists are exppected to have the appropriate training and knowledge about this medication. An accredited education program has been developed by the Society of Obstetricians and Gynaecologists of Canada (SOGC), the College of Family Physicians of Canada, and the Canadian Pharmacists Association, and a free non-accredited course is also available to all pharmacists. The Ontario Pharmacists Association also recommends that pharmacists familiarize themselves with the guidance document developed by the Ontario College of Pharmacists.
Members are encouraged to reach out to OPA with any questions or concerns about reimbursement and claim submissions for Mifepristone/Misoprostol (Mifegymiso) so that we can take your questions forward to the Ministry.